AU2012246999A1 - Method for modulating cytokine activity - Google Patents

Method for modulating cytokine activity Download PDF

Info

Publication number
AU2012246999A1
AU2012246999A1 AU2012246999A AU2012246999A AU2012246999A1 AU 2012246999 A1 AU2012246999 A1 AU 2012246999A1 AU 2012246999 A AU2012246999 A AU 2012246999A AU 2012246999 A AU2012246999 A AU 2012246999A AU 2012246999 A1 AU2012246999 A1 AU 2012246999A1
Authority
AU
Australia
Prior art keywords
hydroxy
hydrogen
substituted
mono
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012246999A
Other languages
English (en)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of AU2012246999A1 publication Critical patent/AU2012246999A1/en
Priority to AU2017203276A priority Critical patent/AU2017203276A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012246999A 2011-04-19 2012-04-18 Method for modulating cytokine activity Abandoned AU2012246999A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203276A AU2017203276A1 (en) 2011-04-19 2017-05-16 Method for modulating cytokine activity

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161476992P 2011-04-19 2011-04-19
US61/476,992 2011-04-19
US201161489516P 2011-05-24 2011-05-24
US61/489,516 2011-05-24
US201161537305P 2011-09-21 2011-09-21
US61/537,305 2011-09-21
US201161548458P 2011-10-18 2011-10-18
US61/548,458 2011-10-18
PCT/JP2012/061004 WO2012144649A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203276A Division AU2017203276A1 (en) 2011-04-19 2017-05-16 Method for modulating cytokine activity

Publications (1)

Publication Number Publication Date
AU2012246999A1 true AU2012246999A1 (en) 2013-10-17

Family

ID=47021806

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012246999A Abandoned AU2012246999A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity
AU2017203276A Abandoned AU2017203276A1 (en) 2011-04-19 2017-05-16 Method for modulating cytokine activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203276A Abandoned AU2017203276A1 (en) 2011-04-19 2017-05-16 Method for modulating cytokine activity

Country Status (13)

Country Link
US (1) US20120270945A1 (enExample)
EP (1) EP2699244A4 (enExample)
JP (1) JP2014511825A (enExample)
KR (1) KR20140043075A (enExample)
CN (2) CN103781482A (enExample)
AU (2) AU2012246999A1 (enExample)
BR (1) BR112013026644A2 (enExample)
CA (1) CA2831869A1 (enExample)
IL (1) IL228700A0 (enExample)
MX (1) MX2013012251A (enExample)
RU (1) RU2013151166A (enExample)
TW (1) TW201247615A (enExample)
WO (1) WO2012144649A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
JP6090723B2 (ja) * 2013-10-04 2017-03-08 国立大学法人東北大学 腎機能障害の予防又は改善剤
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
ATE148344T1 (de) * 1990-04-27 1997-02-15 R Tech Ueno Ltd Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
NZ556710A (en) * 2005-01-27 2010-08-27 Sucampo Ag Method and composition for treating central nervous system disorders
NZ561414A (en) * 2005-03-04 2010-10-29 Sucampo Ag Method and composition for treating peripheral vascular diseases
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
EP1871380B1 (en) * 2005-04-12 2011-10-19 Sucampo AG Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
BRPI0708362A2 (pt) * 2006-02-28 2011-05-24 Sucampo Ag método e composição para o tratamento de doença pulmonar obstrutiva crÈnica
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
WO2009133863A1 (ja) * 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物
NZ608823A (en) * 2010-10-15 2014-11-28 Scinopharm Kunshan Biochemical Technology Co Ltd Processes for preparation of lubiprostone

Also Published As

Publication number Publication date
EP2699244A1 (en) 2014-02-26
AU2017203276A1 (en) 2017-06-08
CN107028952A (zh) 2017-08-11
IL228700A0 (en) 2013-12-31
JP2014511825A (ja) 2014-05-19
MX2013012251A (es) 2014-01-20
CN103781482A (zh) 2014-05-07
BR112013026644A2 (pt) 2016-12-27
KR20140043075A (ko) 2014-04-08
EP2699244A4 (en) 2014-10-22
WO2012144649A1 (en) 2012-10-26
US20120270945A1 (en) 2012-10-25
RU2013151166A (ru) 2015-05-27
NZ616027A (en) 2015-09-25
TW201247615A (en) 2012-12-01
CA2831869A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
AU2017203276A1 (en) Method for modulating cytokine activity
AU2008271982B2 (en) Pharmaceutical combination of NSAID and prostaglandin compound
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
AU2010237744B2 (en) Method and composition for treating macular degeneration
AU2010296307B2 (en) Pharmaceutical combination for treating tumor
US20100305203A1 (en) Method for modulating claudin mediated functions
TWI594751B (zh) 治療帶有腹瀉之腸躁症之方法
US20120277299A1 (en) Method for modulating ion transporter
JP2004521960A (ja) 高眼圧症および緑内障の処置のための方法および組成物
NZ616027B2 (en) Method for modulating cytokine activity
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
US8569279B2 (en) Method for modulating claudin mediated functions
CN103841966A (zh) 治疗精神分裂症的方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted